Home > Category > Signaling Pathways > MAPK/ERK Pathway > MEK > (S)-(3,4-Difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl)methanone;Cobimetinib (GDC-0973; XL518)

(S)-(3,4-二氟-2-((2-氟-4-碘苯基)氨基)苯基)(3-羟基-3-(哌啶-2-基)氮杂环丁烷-1-基)甲酮;考比替尼

ChemLeader 99+%; ee>99%

Catalog No：CL1287 CAS No.：934660-93-2 MDLNo：MFCD22124461 Formula：C21H21F3IN3O2 MW：531.31

Collect Share

Size	Availability	Price(USD)	VIP Price (USD)	Quantity
5 mg	In-stock	￥800.00	Visible after login	- +
10 mg	In-stock	￥1100.00	Visible after login	- +
50 mg	In-stock	￥3000.00	Visible after login	- +

Chemical safety data sheet(MSDS)

Download MSDS

Certificate Of Authenticity(CPA)

Download COA

Inquiry Add To Cart

Product Overview
Related documents
Product details
Related literature

Product Overview

Product Name	(S)-(3,4-Difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl)methanone;Cobimetinib (GDC-0973; XL518)
CAS	934660-93-2
Formula	C21H21F3IN3O2
MW	531.31
MDL	MFCD22124461
Appearance	Off-white solid powder
Storage condition	Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years).

Product details

Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM, and showing no significant inhibition when tested against a panel of more than 100 of serine-threonine and tyrosine kinases. Cobimetinib induces apoptosis. Phase 3.

Related literature

Sorry, there is no relevant literature

Sorry, no related items

History

CL1287

(S)-(3,4-Difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl)methanone;Cobimetinib (GDC-0973; XL518)

934660-93-2 99+%; ee>99%